Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin.
The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, Guangdong Province, China.
Neurologist. 2024 Jan 1;29(1):36-40. doi: 10.1097/NRL.0000000000000518.
The aim of this study was to investigate the outcomes of human urinary kallidinogenase (HUK) after recombinant tissue-type plasminogen activator treatment in patients with acute ischemic stroke (AIS).
In this retrospective study conducted from December 2018 to August 2020, 313 patients with AIS patients who received recombinant tissue-type plasminogen activator treatment were enrolled. Among them, 148 patients received basic therapy, and 165 patients received HUK treatment. Demographics and clinical characteristics were analyzed after treatment, and patients were monitored for stroke recurrence for 12 months. National Institute of Health Stroke Scale (NIHSS) and modified Rankin Scale scores were used to assess the efficacy of treatment. Logistic regression analysis was used to identify risk factors for recurrence.
There were no differences in baseline clinical characteristics between the 2 groups in the database. After 14 days of treatment, the HUK group had significantly lower NIHSS and modified Rankin Scale scores than the control group ( P <0.01). The recurrence rates in the HUK and control groups were 12.84% and 21.82%, respectively, with patients treated with HUK having better outcomes ( P <0.001). Logistic analysis indicated that high homocysteine levels and high NIHSS scores at diagnosis were risk factors for AIS recurrence. In addition, HUK treatment was found to reduce the risk of recurrence.
Treatment with HUK after intravenous thrombolysis can significantly improve the neurological function of AIS patients and reduce stroke recurrence.
本研究旨在探讨重组组织型纤溶酶原激活剂（rt-PA）治疗急性缺血性脑卒中（AIS）患者后人尿激肽原酶（HUK）的结局。
本回顾性研究于 2018 年 12 月至 2020 年 8 月进行，共纳入 313 例接受 rt-PA 治疗的 AIS 患者。其中 148 例接受基础治疗，165 例接受 HUK 治疗。治疗后分析患者的人口统计学和临床特征，并对患者进行 12 个月的卒中复发监测。采用国立卫生研究院卒中量表（NIHSS）和改良 Rankin 量表评分评估治疗效果。采用 logistic 回归分析识别复发的危险因素。
数据库中两组患者的基线临床特征无差异。治疗 14 天后，HUK 组 NIHSS 和改良 Rankin 量表评分均显著低于对照组（P<0.01）。HUK 组和对照组的复发率分别为 12.84%和 21.82%，HUK 治疗组的结果更好（P<0.001）。logistic 分析表明，高同型半胱氨酸水平和诊断时的高 NIHSS 评分是 AIS 复发的危险因素。此外，HUK 治疗可降低复发风险。
静脉溶栓后使用 HUK 治疗可显著改善 AIS 患者的神经功能，降低卒中复发风险。
